[go: up one dir, main page]

BR112015011430A2 - composition for immediate and prolonged release - Google Patents

composition for immediate and prolonged release

Info

Publication number
BR112015011430A2
BR112015011430A2 BR112015011430A BR112015011430A BR112015011430A2 BR 112015011430 A2 BR112015011430 A2 BR 112015011430A2 BR 112015011430 A BR112015011430 A BR 112015011430A BR 112015011430 A BR112015011430 A BR 112015011430A BR 112015011430 A2 BR112015011430 A2 BR 112015011430A2
Authority
BR
Brazil
Prior art keywords
immediate
composition
prolonged release
release
active ingredient
Prior art date
Application number
BR112015011430A
Other languages
Portuguese (pt)
Inventor
Vilasrao Somwanshi Amol
Hagsten Arne
Wannerberger Kristin
Verma Rajan
Boorugu Rambabu
Vinayakrao Barabde Umesh
Ahuja Varinder
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of BR112015011430A2 publication Critical patent/BR112015011430A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

resumo patente de invenção: "composição para liberação imediata e prolongada". a presente invenção refere-se a composições farmacêuticas de dissolução rápida que compreendem um ingrediente ativo para liberação imediata e que compreende adicionalmente uma forma de dosagem de liberação controlada que compreende um ingrediente ativo para liberação controlada.patent summary: "immediate and prolonged release composition". The present invention relates to rapidly dissolving pharmaceutical compositions comprising an active ingredient for immediate release and further comprising a controlled release dosage form comprising an active ingredient for controlled release.

BR112015011430A 2012-11-21 2013-11-21 composition for immediate and prolonged release BR112015011430A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3575DE2012 2012-11-21
IN3947DE2012 2012-12-20
PCT/EP2013/074373 WO2014079922A1 (en) 2012-11-21 2013-11-21 Composition for immediate and extended release

Publications (1)

Publication Number Publication Date
BR112015011430A2 true BR112015011430A2 (en) 2017-07-11

Family

ID=49619947

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015011430A BR112015011430A2 (en) 2012-11-21 2013-11-21 composition for immediate and prolonged release

Country Status (18)

Country Link
EP (1) EP2922525A1 (en)
JP (1) JP2016500088A (en)
KR (1) KR20150085826A (en)
CN (1) CN104797240A (en)
AR (1) AR093585A1 (en)
AU (1) AU2013349682A1 (en)
BR (1) BR112015011430A2 (en)
CA (1) CA2891365A1 (en)
EA (1) EA201590805A1 (en)
HK (1) HK1213779A1 (en)
IL (1) IL238648A0 (en)
IN (1) IN2015DN03984A (en)
MX (1) MX2015006399A (en)
PH (1) PH12015501096A1 (en)
SG (2) SG11201503913TA (en)
TW (1) TW201422254A (en)
WO (1) WO2014079922A1 (en)
ZA (1) ZA201503603B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9814753B2 (en) 2013-07-23 2017-11-14 Serenity Pharmaceuticals Llc Methods and compositions comprising desmopressin in combination with a beta-3-adrenergic receptor agonist
KR20150144209A (en) * 2014-06-16 2015-12-24 훼링 비.브이. Pharmaceutical composition comprising stabilized desmopressin or pharmaceutically acceptable salt thereof
MX2017006655A (en) * 2014-11-20 2018-03-12 Allergan Inc Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist.
BR112017014953A2 (en) 2015-01-12 2018-03-13 Nano Pharmaceutical Laboratories Llc controlled release microglobules in layers and methods for producing them
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
KR20180054655A (en) * 2015-09-01 2018-05-24 웰즐리 파마슈티컬스 엘엘씨 Prolonged, delayed and immediate release formulations
KR20180066113A (en) * 2015-09-30 2018-06-18 웰즐리 파마슈티컬스 엘엘씨 Composition for reducing urinary frequency
WO2017058428A1 (en) * 2015-09-30 2017-04-06 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
TW201726114A (en) * 2015-11-23 2017-08-01 魏斯理製藥公司 Composition for reducing frequency of urination, method of making and use thereof
MX2018007326A (en) * 2015-12-18 2019-03-28 Wellesley Pharmaceuticals Llc Composition for reducing frequency of urination, method of making and use thereof.
EP3445343A1 (en) 2016-04-21 2019-02-27 Valcuria AB Composition and method for pretreating cancer
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN110049757A (en) * 2017-01-11 2019-07-23 辉凌公司 Quickly disintegrated pharmaceutical composition
KR20190021180A (en) * 2017-08-22 2019-03-05 아주대학교산학협력단 Pharmaceutical complex formulations for treating neurodegenerative diseases

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003184A1 (en) 1996-07-19 1998-01-29 Clarke-Garegg, Margaret, A. Levan derivatives, their preparation, composition and applications including medical and food applications
SE9803871D0 (en) * 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
AU2003233118B8 (en) * 2002-05-07 2009-07-30 Ferring Bv Desmopressin in an orodispersible dosage form
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
CN100366294C (en) 2004-04-30 2008-02-06 量子高科（北京）研究院有限公司 Oral cavity quick dissolving preparation and production method thereof
EP1629834A1 (en) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
WO2007029087A2 (en) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Controlled release multiple unit formulations
US20090192228A1 (en) 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
CN102245171A (en) * 2008-11-10 2011-11-16 株式会社爱茉莉太平洋 Slow-release particle and a production method therefor
AU2010277207B2 (en) * 2009-07-31 2014-06-26 Sun Pharmaceutical Industries Limited Multi-layered, multiple unit pharmaceutical compositions
NZ619857A (en) * 2010-03-29 2015-05-29 Ferring Bv A fast dissolving pharmaceutical composition
JO3112B1 (en) * 2010-03-29 2017-09-20 Ferring Bv A fast dissolving pharmaceutical composition
MX356601B (en) * 2010-03-30 2018-05-29 Productos Maver S A De C V Pharmaceutical combination with anti-migraine effect, in solid presentation of extended release.
US20120135050A1 (en) * 2010-07-08 2012-05-31 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Also Published As

Publication number Publication date
IN2015DN03984A (en) 2015-10-02
IL238648A0 (en) 2015-06-30
SG11201503913TA (en) 2015-06-29
CA2891365A1 (en) 2014-05-30
WO2014079922A1 (en) 2014-05-30
AR093585A1 (en) 2015-06-10
MX2015006399A (en) 2015-07-21
JP2016500088A (en) 2016-01-07
HK1213779A1 (en) 2016-07-15
EP2922525A1 (en) 2015-09-30
CN104797240A (en) 2015-07-22
SG10201703388TA (en) 2017-05-30
KR20150085826A (en) 2015-07-24
AU2013349682A1 (en) 2015-06-04
EA201590805A1 (en) 2015-11-30
PH12015501096A1 (en) 2015-07-27
TW201422254A (en) 2014-06-16
ZA201503603B (en) 2016-01-27

Similar Documents

Publication Publication Date Title
BR112015011430A2 (en) composition for immediate and prolonged release
BR112015022972A2 (en) s-ketamine hydrochloride pharmaceutical composition
BR112013031268A8 (en) polypeptides
MX2015008628A (en) Boronic acid derivatives and therapeutic uses thereof.
MX2015008627A (en) Boronic acid derivatives and therapeutic uses thereof.
BR112015000578A2 (en) complement pathway modulators and their uses
PE20151067A1 (en) AUTOTAXIN INHIBITORS
PE20150092A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE
EA201690102A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYLFUMATE FOR INTRODUCTION TO LOW DAILY DOSE
MX2013003365A (en) Pharmaceutical composition.
BR112015000229A2 (en) stable aqueous formulations of etanercept
BR112014005025A2 (en) pharmaceutical composition for use in the treatment of a neurodegenerative disease
CL2012001836A1 (en) Pyrazole compounds, crth2 antagonist; pharmaceutical composition; use in the treatment of inflammatory, infectious, immunoregulatory disorders, respiratory diseases, gastrointestinal or ailments, among others.
BR112012024673A2 (en) thermogelling anesthetic composition
BR112013008601A8 (en) CLEVIDIPINE EMULSION FORMULATIONS CONTAINING ANTIMICROBIAL AGENTS
CL2014003503A1 (en) Pharmaceutical composition for intramammary use comprising a phosphonic acid and at least one antimicrobial agent; and use for the treatment or prevention of mastitis in non-human mammals.
UY33530A (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY AND INFLAMMATORY DISEASES
PE20150353A1 (en) DERIVATIVES OF ESTRA-1,3,5 (10), 16-TETRAENO 3-SUBSTITUTED, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES
BR112014032759A2 (en) racecadotril lipid compositions
BR112017012406A2 (en) fixed ratio formulation of insulin glargine / lixisenatide
BR112015023387A2 (en) racecodotril lipid compositions
BR112013024824A2 (en) Isopentyl esters for use in cosmetic, dermatological or pharmaceutical compositions
MX2016001422A (en) Pharmaceutical compositions of fingolimod.
CU24163B1 (en) TYPICAL OPHTHALMOLOGICAL PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB
CL2016001094A1 (en) Microporous zirconium silicate for the treatment of hyperkalemia.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements